" class="no-js "lang="en-US"> Arcensus has Appointed Prof. Dr. Arndt Rolfs as New CEO - Medtech Alert
Friday, March 01, 2024

Arcensus has Appointed Prof. Dr. Arndt Rolfs as New CEO

Arcensus, a commercial-stage digital healthcare and diagnostics company that empowers people to take control of their health is pleased to announce that Founder, Prof. Dr. Arndt Rolfs, a multi-entrepreneur in biotech and former CEO of several innovative biotech companies, including Nasdaq-listed company CENTOGENE, has been appointed as the Chief Executive Officer of Arcensus GmbH.

Prof. Rolfs has succeeded the role from Mr. Michael Schlenk and assumed the responsibilities of CEO on January 01, 2022. We are very grateful for the hard work and dedication of Mr. Schlenk for successfully performing the duties of CEO in 2021 and constructing the organization of Arcensus. Arcensus are reassured that Mr. Schlenk will continue supporting Arcensus as an active member of the supervisory board.

Mr Schlenk wished the new CEO every success: “I wish Arndt and the operational team all the best for 2022. There is no doubt that this year will bring great progress for Arcensus after building the company so successfully in a record time. I look forward to supporting the shaping of the business model as a member of the Supervisory Board.”

Prof Rolfs is an experienced biotech entrepreneur who knows the necessities and challenges of the healthcare industry very well. Under his leadership, Arcensus will disrupt the genetic diagnostics market through the rapid expansion of its global genomic service and develop new concepts based on genomic knowledge generated worldwide. Arcensus’ genomic data already has a diagnostic yield of about 80% in all genetically suspect patients.

Prof Rolfs said: “Our expertise in the high-quality interpretation of Whole Genome DNA Sequencing data reflects the next revolution in modern medicine. Our global genomic knowledge will help pharma partners accelerate the development of new drugs, especially for rare diseases.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more